Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects

• Status: Active, not recruiting
• Trial end date: 2023-06-30
• Target enrollment: 0
• Participant gender: Male

Summary

This study will assess the safety, tolerability, and pharmacokinetics of DS-6016a after subcutaneous injection in healthy Japanese participants.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Daiichi Sankyo Co., Ltd.

Criteria

Inclusion Criteria:

• Japanese healthy male subjects.

• Age ≥20 and ≤45 years upon providing informed consent.

• Body mass index (BMI) ≥18.5 and <25.0 kg/m^2 at screening.

Exclusion Criteria:

• Have a history of hypersensitivity to any drugs or substances, or being idiosyncratic (eg, having penicillin allergy)

• Have alcohol or drug dependence, etc.